Sorrento Therapeutics Inc
OTC:SRNE

Watchlist Manager
Sorrento Therapeutics Inc Logo
Sorrento Therapeutics Inc
OTC:SRNE
Watchlist
Price: 0.0025 USD 92.31% Market Closed
Market Cap: 1.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+88%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

SRNE Price Targets Summary
Sorrento Therapeutics Inc

There are no price targets for SRNE.
SRNE Lowest Forecast
Wall Street Target
Not Available
SRNE Average Forecast
Wall Street Target
Not Available
SRNE Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Sorrento Therapeutics Inc Competitors:
Price Targets
S
2696
Shanghai Henlius Biotech Inc
21% Downside
MGNX
MacroGenics Inc
195% Upside
ITOS
Iteos Therapeutics Inc
18% Upside
ATYR
aTyr Pharma Inc
242% Upside
S
2696
Shanghai Henlius Biotech Inc
21% Downside
MGNX
MacroGenics Inc
195% Upside
ITOS
Iteos Therapeutics Inc
18% Upside
ATYR
aTyr Pharma Inc
242% Upside
6160
Beigene Ltd
25% Upside
OPK
OPKO Health Inc
130% Upside
GILD
Gilead Sciences Inc
6% Upside
S
SVE
Synthaverse SA
31% Upside

Revenue
Forecast

Revenue Estimate
Sorrento Therapeutics Inc

For the last 8 years the compound annual growth rate for Sorrento Therapeutics Inc's revenue is 42%. The projected CAGR for the next 3 years is 88%.

42%
Past Growth
88%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sorrento Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sorrento Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-79%
Average Miss
What are analyst estimates?

See Also

Summary
SRNE intrinsic value, competitors valuation, and company profile.
DCF Valuation
SRNE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SRNE stock valuation using valuation multiples.
Wall Street Estimates
SRNE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SRNE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SRNE's stock price target?
Not Available

SRNE doesn't have any price targets made by Wall Street professionals.

What is Sorrento Therapeutics Inc's Revenue forecast?
Projected CAGR
88%

For the last 8 years the compound annual growth rate for Sorrento Therapeutics Inc's revenue is 42%. The projected CAGR for the next 3 years is 88%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.